Market Overview

UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs

Share:
Related BMY
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
FDA Decisions In November: The Month In Review
3 Things In Biotech You Should Learn Today: December 15, 2017 (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Equal-Weight to Overweight, and raised the price target from $45.00 to $60.00.

In the report, Morgan Stanley noted, “Upgrading to OW and raising PT from $45 to $60 after raising 2020E EPS by 27%; $60 PT is up 23% from Friday's close. BMY is the leading contender to transform cancer treatment with new drugs that boost the immune system.”

Bristol-Myers Squibb Co. closed on Friday at $48.77.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2017Credit SuisseMaintainsNeutral
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Partner Center